Global Cognition and Memory Enhancement Drugs Market is Estimated to Reach $5 Billion by 2025, Says Accurize Market Research
Global Cognition and Memory Enhancement Drugs Market report published by Accurize Market Research forecast that the global market is expected to reach $5 billion by 2025; growing at a CAGR of 8.8% from 2017 to 2025. By geography, Asia Pacific and North America are expected to grow at a CAGR of XX% and XX%, respectively, during the forecast period.
To browse the complete report, visit at https://www.accurizemarketresearch.com/report/cognition-and-memory-enhancement-drugs-market
Surge in elderly population and increase in occurrence of neurological & memory-related ailments to drive the growth of the market
Surge in elderly population and increase in occurrence of neurological & memory-related ailmentsfuelthe demand for the global cognition and memory enhancement drugs market.Furthermore,increasing healthcare expenditures, benefits offered by cognitive drugs such as enhanced memory and reasoning and increasing economiesalso boost the growth of the market.
The global cognition and memory enhancement drugs market has been bifurcated on the basis of product type, application and geography. Product type segment is further segmented into ADHD (attention deficit hyperactivity disorder); MPH (Methylphenidate). Application segment includes Alzheimer’s disease, education sector, sports and other applications. By geography the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW).
Top players in the market
The key players operational in the market includes Accelerated Intelligence Inc., Allergan Plc., Alternascript LLC, Cambridge Cognition, Ceretropic, Cognition Therapeutics Inc., Cogstate Ltd., HVMN, Nootriment, Novartis Ag, Onnit Labs LLC, Peak Nootropics, Pfizer Inc., Purelife Bioscience Co. Ltd., Shire and Supnootropic Bio Co. Ltd., among others.
Head - Sales
Accurize Market Research
K-129, PC COLONY, HANUMAN NAGAR,